A citation-based method for searching scientific literature

Ele Ferrannini, Simona Baldi, Juan P Frías, Cristian Guja, Elise Hardy, Enrico Repetto, Serge A Jabbour, Ralph A DeFronzo. Diabetes Obes Metab 2020
Times Cited: 2







List of co-cited articles
1 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C Broedl, Hans-Juergen Woerle. J Clin Invest 2014
634
100

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
50

Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.
Peter Ueda, Henrik Svanström, Mads Melbye, Björn Eliasson, Ann-Marie Svensson, Stefan Franzén, Soffia Gudbjörnsdottir, Kristian Hveem, Christian Jonasson, Björn Pasternak. BMJ 2018
145
50

Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Ele Ferrannini, Simona Baldi, Silvia Frascerra, Brenno Astiarraga, Tim Heise, Roberto Bizzotto, Andrea Mari, Thomas R Pieber, Elza Muscelli. Diabetes 2016
283
50

Polypharmacy: which drug combinations make sense?
L E Hollister. Hosp Community Psychiatry 1982
8
50

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
732
50


Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes.
Iliana C Lega, Susan E Bronskill, Michael A Campitelli, Jun Guan, Nathan M Stall, Kenneth Lam, Lisa M McCarthy, Andrea Gruneir, Paula A Rochon. Diabetes Obes Metab 2019
36
50

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
Brendon L Neuen, Tamara Young, Hiddo J L Heerspink, Bruce Neal, Vlado Perkovic, Laurent Billot, Kenneth W Mahaffey, David M Charytan, David C Wheeler, Clare Arnott,[...]. Lancet Diabetes Endocrinol 2019
242
50

Euglycaemic diabetic ketoacidosis in patients using sodium-glucose co-transporter 2 inhibitors.
Michelle Isaacs, Katherine T Tonks, Jerry R Greenfield. Intern Med J 2017
13
50

US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States.
Rajiv Saran, Bruce Robinson, Kevin C Abbott, Jennifer Bragg-Gresham, Xiaoying Chen, Debbie Gipson, Haoyu Gu, Richard A Hirth, David Hutton, Yan Jin,[...]. Am J Kidney Dis 2020
233
50

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, David R Matthews, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Mehul Desai, Qiang Li, Hsiaowei Deng,[...]. Circulation 2018
132
50



Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use.
Louis Potier, Ronan Roussel, Gilberto Velho, Pierre-Jean Saulnier, Anisoara Bumbu, Odette Matar, Fabrice Schneider, Stéphanie Ragot, Michel Marre, Kamel Mohammedi,[...]. Diabetologia 2019
21
50



A Pilot Study Embedding Clinical Pharmacists Within an Interprofessional Nephrology Clinic for the Initiation and Monitoring of Empagliflozin in Diabetic Kidney Disease.
Laura K Triantafylidis, Chelsea E Hawley, Christopher Fagbote, Jiahua Li, Nicole Genovese, Julie M Paik. J Pharm Pract 2021
4
50

Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study.
Jenny E Blau, Viviana Bauman, Ellen M Conway, Paolo Piaggi, Mary F Walter, Elizabeth C Wright, Shanna Bernstein, Amber B Courville, Michael T Collins, Kristina I Rother,[...]. JCI Insight 2018
47
50

Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature.
Benedetta Maria Bonora, Angelo Avogaro, Gian Paolo Fadini. Diabetes Obes Metab 2018
41
50

Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus.
Joanna Sophia J Vinke, Hiddo J L Heerspink, Martin H de Borst. Curr Opin Nephrol Hypertens 2019
7
50


Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis.
Wei-Jie Guan, Wen-Hua Liang, Yi Zhao, Heng-Rui Liang, Zi-Sheng Chen, Yi-Min Li, Xiao-Qing Liu, Ru-Chong Chen, Chun-Li Tang, Tao Wang,[...]. Eur Respir J 2020
50

Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Damayanthi Devineni, Christopher R Curtin, Thomas C Marbury, William Smith, Nicole Vaccaro, David Wexler, An Vandebosch, Sarah Rusch, Hans Stieltjes, Ewa Wajs. Clin Ther 2015
29
50


Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis.
Jiali Liu, Ling Li, Sheyu Li, Pengli Jia, Ke Deng, Wenwen Chen, Xin Sun. Sci Rep 2017
86
50

Candida sp. Infections in Patients with Diabetes Mellitus.
Célia F Rodrigues, Maria Elisa Rodrigues, Mariana Henriques. J Clin Med 2019
55
50



Development of SGLT1 and SGLT2 inhibitors.
Timo Rieg, Volker Vallon. Diabetologia 2018
90
50

Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria.
Suzanne Geerlings, Vivian Fonseca, David Castro-Diaz, James List, Shamik Parikh. Diabetes Res Clin Pract 2014
126
50

SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission.
Peter S Hamblin, Rosemary Wong, Elif I Ekinci, Spiros Fourlanos, Sonali Shah, Alicia R Jones, Matthew J L Hare, Genevieve L Calder, Dilan Seneviratne Epa, Elizabeth M George,[...]. J Clin Endocrinol Metab 2019
38
50

Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
Tadashi Toyama, Brendon L Neuen, Min Jun, Toshiaki Ohkuma, Bruce Neal, Meg J Jardine, Hiddo L Heerspink, Muh Geot Wong, Toshiharu Ninomiya, Takashi Wada,[...]. Diabetes Obes Metab 2019
88
50

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
50

Renal physiology of glucose handling and therapeutic implications.
David Z Cherney, Mehmet Kanbay, Julie A Lovshin. Nephrol Dial Transplant 2020
19
50



Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial.
Christopher P Cannon, Vlado Perkovic, Rajiv Agarwal, James Baldassarre, George Bakris, David M Charytan, Dick de Zeeuw, Robert Edwards, Tom Greene, Hiddo J L Heerspink,[...]. Circulation 2020
49
50


Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial.
Mark E Cooper, Silvio E Inzucchi, Bernard Zinman, Stefan Hantel, Maximilian von Eynatten, Christoph Wanner, Audrey Koitka-Weber. Am J Kidney Dis 2019
25
50

Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.
Beatrice C Lupsa, Silvio E Inzucchi. Diabetologia 2018
62
50


Potential Hypoxic Renal Injury in Patients With Diabetes on SGLT2 Inhibitors: Caution Regarding Concomitant Use of NSAIDs and Iodinated Contrast Media.
Samuel N Heyman, Mogher Khamaisi, Seymour Rosen, Christian Rosenberger, Zaid Abassi. Diabetes Care 2017
21
50



The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.
Sreeneeranj Kasichayanula, Xiaoni Liu, Melanie Pe Benito, Ming Yao, Marc Pfister, Frank P LaCreta, William Griffith Humphreys, David W Boulton. Br J Clin Pharmacol 2013
78
50

The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus.
V Sahasrabudhe, S G Terra, A Hickman, D Saur, H Shi, M O'Gorman, Z Zhou, D L Cutler. J Clin Pharmacol 2017
30
50

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
50

Sodium Glucose Cotransporter 2 Inhibition Heralds a Call-to-Action for Diabetic Kidney Disease.
Katherine R Tuttle, David Z Cherney. Clin J Am Soc Nephrol 2020
10
50

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Christoph Wanner, John M Lachin, Silvio E Inzucchi, David Fitchett, Michaela Mattheus, Jyothis George, Hans J Woerle, Uli C Broedl, Maximilian von Eynatten, Bernard Zinman. Circulation 2018
217
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.